top of page
Onchilles Pharma
newsroom
Press Release
Jan 133 min read
Onchilles Expands Leadership Team to Advance First-in-Class Pan-Cancer Therapeutics Targeting the ELANE Pathway into Clinical Trials
January 13, 2024 SAN DIEGO, January 13, 2024 – Onchilles Pharma , a private biotech company pioneering pan-cancer therapeutics that...
Press Release
Nov 7, 20243 min read
Onchilles Pharma Presents New Preclinical Data for the Systemically Delivered NEU-002 Program Targeting the ELANE Pathway at SITC 2024
November 7, 2024 Novel Intravenous Therapeutic Candidate Demonstrates Pan-Cancer Efficacy and Immunogenic Cell Death in Preclinical...
Press Release
Oct 4, 20242 min read
Onchilles Pharma Announces Presentation of Data for the NEU-002 Program at SITC 2024
October 4, 2024 SAN DIEGO, October 4, 2024 – Onchilles Pharma , a private biotech company developing pan-cancer therapeutics that...
Onchilles News
Jun 24, 20241 min read
PharmaShots: Onchilles Pharma at AACR 2024: Lev Becker in a Stimulating Conversation with PharmaShots
Onchilles Pharma unveiled findings at AACR 2024 from the late-stage preclinical data of its two candidates: N17350 and N17465 ( read the...
Onchilles News
Apr 22, 20241 min read
SDBJ: Onchilles Pharma Shares Promising Preclinical Data; New Mechanism Discovered Could Treat Wide Range of Cancers
April 23, 2024 Jeff Clemetson of the San Diego Business Journal talked with Onchilles after the Company’s presenation at AACR 2024 of new...
Press Release
Apr 9, 20244 min read
Onchilles Pharma Presents at AACR 2024 New Preclinical Data for N17350 and N17465 Demonstrating the Potential for Potent and Tumor-Selective Treatment
April 9, 2024 Tumor-directed N17350 and systemically delivered N17465 are based on the breakthrough discovery of a novel innate immune...
Press Release
Mar 6, 20242 min read
Onchilles Pharma Announces Two Presentations of New Preclinical Data for N17350 and N17465 at AACR 2024
March 6, 2024 SAN DIEGO, March 6, 2024 – Onchilles Pharma , a private biotech company developing cancer therapeutics that leverage a...
Onchilles News
Jan 5, 20241 min read
Drug Target Review: Transforming Cancer Treatment for Greatest Impact
January 5, 2024 In this Q&A with Drug Target Review , Dr Lev Becker, Associate Professor, University of Chicago and Cofounder of...
Press Release
Nov 2, 20233 min read
Onchilles Pharma Presents at SITC 2023 New Preclinical Data for N17350, a Potential Pan-Cancer Therapeutic
November 3, 2023 SAN DIEGO, November 3, 2023 – Onchilles Pharma , a private biotech company developing cancer therapeutics that leverage...
Press Release
Sep 27, 20232 min read
Onchilles Pharma Announces Presentation of Data for N17350 Program at SITC 2023
September 27, 2023 SAN DIEGO, September 27, 2023 – Onchilles Pharma , a private biotech company developing new pan-cancer therapeutics...
Press Release
Apr 18, 20233 min read
Onchilles Pharma Presents at AACR 2023 New Preclinical Data on N17350, a First-in-Class Immuno-Oncology Drug Candidate with Broad, Potent, and Direct Tumor Killing Activity
April 19, 2023 N17350 is the first drug candidate from Onchilles’ platform that is based on the breakthrough discovery of a novel...
Press Release
Mar 13, 20232 min read
Onchilles Pharma Announces Presentation of Preclinical Data for N17350 at AACR 2023
March 14, 2023 The drug candidate, N17350, leverages the neutrophil elastase (ELANE) pathway, to achieve broad cancer-killing activity...
Press Release
Dec 12, 20223 min read
Onchilles Pharma Nominates First Drug Development Candidate Targeting Neutrophil Biology for the Treatment of Cancer
December 12, 2022 The drug candidate, N17350, leverages the neutrophil elastase (ELANE) pathway, to achieve broad cancer-killing activity...
Onchilles News
Jun 19, 20211 min read
SDBJ: Onchilles Pharma Raises $7M for Targeted Cancer Therapy
June 20, 2021 Natallie Rocha of the San Diego Business Journal talked with Onchilles after the announcement of a $7 million Series A...
Onchilles News
Jun 14, 20211 min read
BioWorld: Onchilles looks for cancer’s Achilles heel with a $7M series A
June 15, 2021 Lev Becker spent about six years studying how to release neutrophile elastase from human neutrophils so it could select...
Press Release
Jun 9, 20213 min read
Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway
June 10, 2021 Foundational research published today in Cell is the first to describe ELANE, a major anti-cancer protein released by human...
Onchilles News
Jun 9, 20211 min read
Could neutrophils be the secret to cancer’s Achilles’ heel?
June 10, 2021 A study published in the June 10, 2021 issue of Cell describes a remarkable new mechanism by which the body’s own immune...
Onchilles News
Jun 9, 20211 min read
Cancer’s Achilles Heel? UChicago Startup Secures $7 Million to Develop Unique Treatment
June 10, 2021 Onchilles Pharma recently closed its Series A funding round, bringing in approximately $7 million, including a $500,000...
Onchilles News
Jun 7, 20211 min read
Nature Reviews Drug Discovery: A Protease with Far-Reaching Anti-Cancer Effects
June 8, 2021 Although cancer therapies are becoming increasingly specific to the tumour and mutation type, a potent tumour-agnostic and...
Onchilles News
May 20, 20211 min read
Cancer Discovery: The Serine Protease Neutrophil Elastase Selectively Kills Tumor Cells
May 21, 2021 Neutrophil elastase (ELANE) killed tumors of diverse types but spared neighboring healthy tissue. To read the full article,...
pioneering the use of the ELANE pathway to create the next-generation of pan-cancer therapeutics
bottom of page